Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentLiab,otherAssets,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,ERGO,-2153258.0,33660900,,,-432777,,-432777,371606,35866,-335740,-335740,,-43596,,,,0,45986,381726,10120,-97037,,-432777,-432777,186509.0,12486728.0,2405702.0,-1966749.0,439141.0,28150.0,-14472774.0,-8853.0,76050.0,2105624.0,11369.0,-8853.0,18285.0,234347.0,7973.0,300078.0,69759.0,652652.0,,,-96807.0,497868.0,513986.0,-822.0,74030.0,-439956.0,3493.0,-6090.0,-2243.0,16118.0,74201.0,,-1871277.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.08 - 0.088,0.088,0.0,0.0,0,0,finmb_36170260,Other OTC,"Entia Biosciences, Inc.",USD,197376,160616,0.078,7.8,0.01 - 0.39,-0.302,-0.774359,0.01,0.39,-14400000,False,False,USD,REGULAR,-0.05,-0.07,0.119166665,-0.031166665,-0.26153845,0.06507246,0.022927538,0.35233855,1373187,-1.2571429,15,America/New_York,EDT,ENTIA BIOSCIENCES INC,0.088,1630504545,0.0,0.08,0.088,0.08,19700,0,PNK,4,us_market,1.29,,,0.39,0.01,0.1192,0.0651,197.38k,160.62k,33.66M,,22.64M,0.00%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Feb 14, 2012","Dec 30, 2016","Dec 30, 2016",0.00%,-439.75%,-164.37%,,265.47k,0.01,-32.80%,173.97k,-1.15M,-1.4M,-0.0500,,76.05k,0,1.05M,,0.11,-0.07,-715.1k,-290.65k,Value,97140,Healthcare,6,"Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.",Sherwood,971-228-0709,OR,1483142400,United States,http://www.entiabio.com,86400,13565 SW Tualatin-Sherwood Road,503-610-1876,Biotechnology,Suite 800
t-1,ERGO,-1880101.0,33660900,,,-288776,,-288776,299799,28426,-271373,-271373,,-14634,,,,0,41855,313228,13429,-17403,,-288776,-288776,236404.0,12386996.0,2009336.0,-1643697.0,365827.0,28146.0,-14039997.0,-18842.0,2020.0,1710689.0,,-18842.0,21779.0,72644.0,5730.0,298647.0,28669.0,691308.0,6283.0,35000.0,157196.0,62294.0,57876.0,15110.0,-15738.0,-73614.0,4734.0,4411.0,4226.0,-4418.0,27513.0,,-1638045.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.08 - 0.088,0.088,0.0,0.0,0,0,finmb_36170260,Other OTC,"Entia Biosciences, Inc.",USD,197376,160616,0.078,7.8,0.01 - 0.39,-0.302,-0.774359,0.01,0.39,-14400000,False,False,USD,REGULAR,-0.05,-0.07,0.119166665,-0.031166665,-0.26153845,0.06507246,0.022927538,0.35233855,1373187,-1.2571429,15,America/New_York,EDT,ENTIA BIOSCIENCES INC,0.088,1630504545,0.0,0.08,0.088,0.08,19700,0,PNK,4,us_market,1.29,,,0.39,0.01,0.1192,0.0651,197.38k,160.62k,33.66M,,22.64M,0.00%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Feb 14, 2012","Dec 30, 2016","Dec 30, 2016",0.00%,-439.75%,-164.37%,,265.47k,0.01,-32.80%,173.97k,-1.15M,-1.4M,-0.0500,,76.05k,0,1.05M,,0.11,-0.07,-715.1k,-290.65k,Value,97140,Healthcare,6,"Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.",Sherwood,971-228-0709,OR,1483142400,United States,http://www.entiabio.com,86400,13565 SW Tualatin-Sherwood Road,503-610-1876,Biotechnology,Suite 800
t-2,ERGO,-1627749.0,33660900,,,-401631,,-401631,353181,62832,-290349,-290349,,-17888,,,,0,98425,388774,35593,-111282,,-401631,-401631,237503.0,12362707.0,1789856.0,-1390246.0,399798.0,28142.0,-13751218.0,-29877.0,17758.0,1492641.0,,-29877.0,25414.0,81881.0,9956.0,297215.0,13080.0,659204.0,4188.0,55000.0,228418.0,134381.0,122681.0,15596.0,17758.0,-102335.0,4735.0,18139.0,-450.0,-11700.0,31262.0,-2588.0,-1410760.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.08 - 0.088,0.088,0.0,0.0,0,0,finmb_36170260,Other OTC,"Entia Biosciences, Inc.",USD,197376,160616,0.078,7.8,0.01 - 0.39,-0.302,-0.774359,0.01,0.39,-14400000,False,False,USD,REGULAR,-0.05,-0.07,0.119166665,-0.031166665,-0.26153845,0.06507246,0.022927538,0.35233855,1373187,-1.2571429,15,America/New_York,EDT,ENTIA BIOSCIENCES INC,0.088,1630504545,0.0,0.08,0.088,0.08,19700,0,PNK,4,us_market,1.29,,,0.39,0.01,0.1192,0.0651,197.38k,160.62k,33.66M,,22.64M,0.00%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Feb 14, 2012","Dec 30, 2016","Dec 30, 2016",0.00%,-439.75%,-164.37%,,265.47k,0.01,-32.80%,173.97k,-1.15M,-1.4M,-0.0500,,76.05k,0,1.05M,,0.11,-0.07,-715.1k,-290.65k,Value,97140,Healthcare,6,"Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.",Sherwood,971-228-0709,OR,1483142400,United States,http://www.entiabio.com,86400,13565 SW Tualatin-Sherwood Road,503-610-1876,Biotechnology,Suite 800
t-3,ERGO,-1262838.0,33660900,,,-272592,,-272592,316754,46843,-269911,-269911,,-7394,,,,0,79200,349111,32357,-2681,,-272592,-272592,236014.0,12335533.0,1432408.0,-1026824.0,405772.0,28138.0,-13349584.0,-40911.0,,1279581.0,,-40911.0,29050.0,85708.0,9506.0,152827.0,31219.0,616179.0,,55000.0,124134.0,79589.0,79589.0,14759.0,-24133.0,-99193.0,4735.0,9104.0,-2408.0,-11700.0,22224.0,-4529.0,-1193873.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.08 - 0.088,0.088,0.0,0.0,0,0,finmb_36170260,Other OTC,"Entia Biosciences, Inc.",USD,197376,160616,0.078,7.8,0.01 - 0.39,-0.302,-0.774359,0.01,0.39,-14400000,False,False,USD,REGULAR,-0.05,-0.07,0.119166665,-0.031166665,-0.26153845,0.06507246,0.022927538,0.35233855,1373187,-1.2571429,15,America/New_York,EDT,ENTIA BIOSCIENCES INC,0.088,1630504545,0.0,0.08,0.088,0.08,19700,0,PNK,4,us_market,1.29,,,0.39,0.01,0.1192,0.0651,197.38k,160.62k,33.66M,,22.64M,0.00%,0.00%,,,,,,,,,,,0.00%,,,1:10,"Feb 14, 2012","Dec 30, 2016","Dec 30, 2016",0.00%,-439.75%,-164.37%,,265.47k,0.01,-32.80%,173.97k,-1.15M,-1.4M,-0.0500,,76.05k,0,1.05M,,0.11,-0.07,-715.1k,-290.65k,Value,97140,Healthcare,6,"Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.",Sherwood,971-228-0709,OR,1483142400,United States,http://www.entiabio.com,86400,13565 SW Tualatin-Sherwood Road,503-610-1876,Biotechnology,Suite 800
